The primary targets for Hepatitis C campaigns are mainly the intravenous drug users who share needles to administer their drugs. It is estimated that about 170 million people are infected with the virus globally. Approximately 3.2 million Americans suffer from Hepatitis C with 75 percent of those patients developing acute Hepatitis C. This is about 3 percent of the population worldwide (Norton, 2012). Four million new infections are reported annually making the disease a prominent public health concern (Hicks,
